M
Description
Clinical-stage pharmaceutical company, subsidiary of Harrow Inc. (HROW), developing non-IV, non-opioid sublingual tablets for sedation and analgesia in medical procedures. Its candidate MELT-300 (midazolam + ketamine, Zydis® technology) successfully passed the pivotal Phase 3 trial for cataract surgery.